Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta(b)pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxylate
2. Bms-927711
3. Nurtec Odt
4. Rimegepant
1. Nurtec Odt
2. Rimegepant Sulfate [usan]
3. 1374024-48-2
4. 1383nm3q0h
5. Rimegepant Sulfate (usan)
6. 1-piperidinecarboxylic Acid, 4-(2,3-dihydro-2-oxo-1h-imidazo(4,5-b)pyridin-1-yl)-, (5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta(b)pyridin-9-yl Ester, Sulfate, Hydrate (2:1:3)
7. Di((5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta(b)pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxylate), Monosulfate, Trihydrate
8. Unii-1383nm3q0h
9. Nurtec Odt (tn)
10. Rimegepant Sulfate Dihydrate
11. Chembl2364629
12. Dtxsid60160174
13. Rimegepant Sulfate [who-dd]
14. Rimegepant Sulfate [orange Book]
15. Rimegepant Hemisulfate Sesquihydrate
16. D10663
17. Rimegepant Hemisulfate Sesquihydrate [mi]
18. Q27251488
Molecular Weight | 1221.2 g/mol |
---|---|
Molecular Formula | C56H64F4N12O13S |
Hydrogen Bond Donor Count | 9 |
Hydrogen Bond Acceptor Count | 23 |
Rotatable Bond Count | 8 |
Exact Mass | 1220.43726396 g/mol |
Monoisotopic Mass | 1220.43726396 g/mol |
Topological Polar Surface Area | 313 Ų |
Heavy Atom Count | 86 |
Formal Charge | 0 |
Complexity | 973 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 6 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 6 |
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Rimegepant is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Migraine Disorders.
Lead Product(s): Rimegepant Sulfate,Zavegepant HCl
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Other Small Molecule
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 22, 2025
Lead Product(s) : Rimegepant Sulfate,Zavegepant HCl
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Acute Migraine Treatment in the ED with Gepants
Details : Rimegepant is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Migraine Disorders.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 22, 2025
Details:
Undisclosed
Lead Product(s): Rimegepant Sulfate,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 15, 2024
Lead Product(s) : Rimegepant Sulfate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 15, 2024
Details:
Undisclosed
Lead Product(s): Rimegepant Sulfate,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 27, 2024
Lead Product(s) : Rimegepant Sulfate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 27, 2024
Details:
Undisclosed
Lead Product(s): Rimegepant Sulfate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 24, 2024
Lead Product(s) : Rimegepant Sulfate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison of Rimegepant and Placebo for Pain in IBS
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 24, 2024
Details:
Vydura (also known as Rimegepant) is an oral lyophilisate and is the first calcitonin gene-related peptide (CGRP) receptor antagonist migraine therapy to be accepted by the SMC.
Lead Product(s): Rimegepant Sulfate,Inapplicable
Therapeutic Area: Neurology Brand Name: Vydura
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Biohaven Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 05, 2023
Lead Product(s) : Rimegepant Sulfate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Biohaven Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
First-In-Class Migraine Treatment Vydura Approved for NHS Scotland
Details : Vydura (also known as Rimegepant) is an oral lyophilisate and is the first calcitonin gene-related peptide (CGRP) receptor antagonist migraine therapy to be accepted by the SMC.
Product Name : Vydura
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 05, 2023
Details:
Undisclosed
Lead Product(s): Rimegepant Sulfate,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 12, 2023
Lead Product(s) : Rimegepant Sulfate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 12, 2023
Details:
Pfizer will acquire Biohaven, the maker of NURTEC® ODT (rimegepant sulfate). Pfizer will commercialize NURTEC® ODT, an innovative compound for the prevention and acute treatment of migraine.
Lead Product(s): Rimegepant Sulfate,Inapplicable
Therapeutic Area: Neurology Brand Name: Nurtec ODT
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Pfizer Inc
Deal Size: $11,600.0 million Upfront Cash: $11,600.0 million
Deal Type: Acquisition October 05, 2022
Lead Product(s) : Rimegepant Sulfate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : $11,600.0 million
Deal Type : Acquisition
Pfizer to Acquire Biohaven Pharmaceuticals
Details : Pfizer will acquire Biohaven, the maker of NURTEC® ODT (rimegepant sulfate). Pfizer will commercialize NURTEC® ODT, an innovative compound for the prevention and acute treatment of migraine.
Product Name : Nurtec ODT
Product Type : Other Small Molecule
Upfront Cash : $11,600.0 million
October 05, 2022
Details:
Results from long-term studies of Nurtec ODT (Rimegepant Sulfate) as a preventive and acute treatment of migraine showed more than 80% of patients achieved ≥50% reduction in moderate or severe monthly migraine days and approximately half experienced a 100% reduction.
Lead Product(s): Rimegepant Sulfate,Inapplicable
Therapeutic Area: Neurology Brand Name: Nurtec ODT
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 06, 2022
Lead Product(s) : Rimegepant Sulfate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biohaven Underscores Depth of Migraine Portfolio with Data from Nurtec® ODT (rimegepant) Long-Ter...
Details : Results from long-term studies of Nurtec ODT (Rimegepant Sulfate) as a preventive and acute treatment of migraine showed more than 80% of patients achieved ≥50% reduction in moderate or severe monthly migraine days and approximately half experienced a ...
Product Name : Nurtec ODT
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2022
Details:
Undisclosed
Lead Product(s): Rimegepant Sulfate,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 26, 2022
Lead Product(s) : Rimegepant Sulfate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 26, 2022
Details:
Undisclosed
Lead Product(s): Rimegepant Sulfate,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 22, 2022
Lead Product(s) : Rimegepant Sulfate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 22, 2022
Global Sales Information
Company : Biohaven Pharma
Rimegepant Sulfate
Drug Cost (USD) : 478,240,312
Year : 2023
Prescribers : 83811
Prescriptions : 329578
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Biohaven Pharma
Rimegepant Sulfate
Drug Cost (USD) : 276,493,155
Year : 2022
Prescribers : 56513
Prescriptions : 207402
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Biohaven Pharma
Rimegepant Sulfate
Drug Cost (USD) : 118,402,787
Year : 2021
Prescribers : 32315
Prescriptions : 104314
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Biohaven Pharma
Rimegepant Sulfate
Drug Cost (USD) : 18,933,232
Year : 2020
Prescribers : 8957
Prescriptions : 19444
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Dosage Form : Schmelztabl
Dosage Strength : 75mg
Price Per Pack (Euro) : 50.61
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Dosage Form : Schmelztabl
Dosage Strength : 75mg
Price Per Pack (Euro) : 202.53
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Dosage Form : Schmelztabl
Dosage Strength : 75mg
Price Per Pack (Euro) : 404.89
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Market Place
Reply
03 Sep 2025
Reply
17 Jul 2025
Reply
17 Feb 2025
Reply
25 Jan 2025
Reply
29 Aug 2024
Reply
07 Aug 2024
Reply
07 Jul 2022
Reply
04 May 2022
Reply
11 Jan 2021
Reply
12 Dec 2020
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
82
PharmaCompass offers a list of Rimegepant Sulfate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rimegepant Sulfate manufacturer or Rimegepant Sulfate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rimegepant Sulfate manufacturer or Rimegepant Sulfate supplier.
PharmaCompass also assists you with knowing the Rimegepant Sulfate API Price utilized in the formulation of products. Rimegepant Sulfate API Price is not always fixed or binding as the Rimegepant Sulfate Price is obtained through a variety of data sources. The Rimegepant Sulfate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Nurtec odt (TN) manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nurtec odt (TN), including repackagers and relabelers. The FDA regulates Nurtec odt (TN) manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nurtec odt (TN) API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nurtec odt (TN) manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Nurtec odt (TN) supplier is an individual or a company that provides Nurtec odt (TN) active pharmaceutical ingredient (API) or Nurtec odt (TN) finished formulations upon request. The Nurtec odt (TN) suppliers may include Nurtec odt (TN) API manufacturers, exporters, distributors and traders.
click here to find a list of Nurtec odt (TN) suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Nurtec odt (TN) DMF (Drug Master File) is a document detailing the whole manufacturing process of Nurtec odt (TN) active pharmaceutical ingredient (API) in detail. Different forms of Nurtec odt (TN) DMFs exist exist since differing nations have different regulations, such as Nurtec odt (TN) USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Nurtec odt (TN) DMF submitted to regulatory agencies in the US is known as a USDMF. Nurtec odt (TN) USDMF includes data on Nurtec odt (TN)'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nurtec odt (TN) USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Nurtec odt (TN) suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Nurtec odt (TN) Drug Master File in Korea (Nurtec odt (TN) KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Nurtec odt (TN). The MFDS reviews the Nurtec odt (TN) KDMF as part of the drug registration process and uses the information provided in the Nurtec odt (TN) KDMF to evaluate the safety and efficacy of the drug.
After submitting a Nurtec odt (TN) KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Nurtec odt (TN) API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Nurtec odt (TN) suppliers with KDMF on PharmaCompass.
A Nurtec odt (TN) written confirmation (Nurtec odt (TN) WC) is an official document issued by a regulatory agency to a Nurtec odt (TN) manufacturer, verifying that the manufacturing facility of a Nurtec odt (TN) active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Nurtec odt (TN) APIs or Nurtec odt (TN) finished pharmaceutical products to another nation, regulatory agencies frequently require a Nurtec odt (TN) WC (written confirmation) as part of the regulatory process.
click here to find a list of Nurtec odt (TN) suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nurtec odt (TN) as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Nurtec odt (TN) API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Nurtec odt (TN) as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Nurtec odt (TN) and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nurtec odt (TN) NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Nurtec odt (TN) suppliers with NDC on PharmaCompass.
Nurtec odt (TN) Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nurtec odt (TN) GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nurtec odt (TN) GMP manufacturer or Nurtec odt (TN) GMP API supplier for your needs.
A Nurtec odt (TN) CoA (Certificate of Analysis) is a formal document that attests to Nurtec odt (TN)'s compliance with Nurtec odt (TN) specifications and serves as a tool for batch-level quality control.
Nurtec odt (TN) CoA mostly includes findings from lab analyses of a specific batch. For each Nurtec odt (TN) CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nurtec odt (TN) may be tested according to a variety of international standards, such as European Pharmacopoeia (Nurtec odt (TN) EP), Nurtec odt (TN) JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nurtec odt (TN) USP).